Jaguar Gene Therapy
Biotechnology · Cell & Gene Therapy
$139Mlatest round · Series B · Apr 2021 · 5 yr ago
1backers · ARCH Venture Partners
200+team · employees, estimated range
15stories in the press
Overview
At Jaguar Gene Therapy, we believe in a world where patients and families won’t have to hear those words. Our mission is to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases.
Funding and backers
Total raised
$139M
1 round on record
Latest round
$139M
Series B · Apr 2021 · 5 yr ago
Team
201-500
employees, estimated range
Backers
1
ARCH Venture Partners
The money's age
Long since its last round
66 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 13, 2024
Launched Jaguar Gene Therapy Launches with Mission to Accelerate Breakthroughs in Gene Therapy for Patients Suffering from Severe Genetic Diseases · jaguargenetherapy.com
Jan 31, 2024
Certified Jaguar Gene Therapy Announces FDA Clearance of IND to Study JAG201 in a Genetic Form of Autism Spectrum Disorder and Phelan-McDermid Syndrome · jaguargenetherapy.com
Apr 13, 2021
Raised a round Series B $139M · led by Eli Lilly
Feb 2021
Website went live first capture in the Wayback Machine
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Apr 2021 | $139M | Eli Lilly lead, Company Capital lead, Deerfield Management lead | jaguargenetherapy.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Alia Therapeutics is a startup which is developing next-generation gene editing medicines to cure genetic diseases.
We're on a mission to fulfill the promise of genetic medicine for all patients. At Addition, we are advancing a pipeline of therapeutics to…
Search for: At SonomaBio we believe in balance. Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered…
Code Biotherapeutics is an emerging next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to…
Metagenomi is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for…
Instant Quantification of genetic modifications for Cell and Gene Therapies.
Financials
Total raised
$139M
Latest round
Series B
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series B | 2021 | $139M | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
ARCH Venture PartnersVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Report
Report
Jaguar Gene Therapy completes Cohort I patient dosing in JAG201 clinical trial
Jaguar expects to complete enrolment and dosing in Cohort II by the second quarter of 2026.
Read more
Report
Jaguar Gene Therapy Announces Successful Completion of Dosing of First Patient Cohort in Clinical Trial Evaluating JAG201 for the Treatment of a Leading Monogenic Cause of Autism Spectrum Disorder Known as Phelan-McDermid Syndrome
Dosing of Cohort 1 complete with first three patients having received starting dose of JAG201 delivered via intracerebroventricular (ICV) injection First two patients in dose-escalation Cohort 2 have been dosed, and company anticipates target enrollment a
Read more
Report
Andelyn Biosciences Announces Partnership with Jaguar Gene Therapy to Provide Late-Stage PPQ Manufacturing Newswise
Andelyn Biosciences, a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Jaguar Gene Therapy to perform late-stage Process Performance Qualification (PPQ) manufacturing of JAG2
Read more
Report
Jaguar Gene Therapy to Initiate Inaugural Pediatric Clinical Trial Targeting a Genetic Form of Autism Spectrum Disorder and Phelan-McDermid Syndrome
The company recently conducted a Type C meeting with the U.S. Food and Drug Administration (FDA) and is cleared to proceed with dosing of pediatric patients (2+ years) with JAG201 with expansion into adults (18+ years) following the pediatric cohort The f
Read more
Report
Jaguar Gene Therapy Launches with Mission to Accelerate Breakthroughs in Gene Therapy for Patients Suffering from Severe Genetic Diseases
Read more
Report
Jaguar Gene Therapy Announces FDA Clearance of IND to Study JAG201 in a Genetic Form of Autism Spectrum Disorder and Phelan-McDermid Syndrome
#top .av-special-heading.av-l30ugp1x-d41cb3ddf7884fc87603fddc7f272534{ padding-bottom:10px; } body .av-special-heading.av-l30ugp1x-d41cb3ddf7884fc87603fddc7f272534 .av-special-heading-tag .heading-char{ font-size:25px; } .av-special-heading.av-l30ugp1x-d4
Read more
Report
New Resource for the Galactosemia Community Launches to Empower Families as They Navigate Lifelong Genetic Disease
#top .av-special-heading.av-l30ugp1x-c65c6af75a9f33e7af0f8475b59f0a8a{ padding-bottom:10px; } body .av-special-heading.av-l30ugp1x-c65c6af75a9f33e7af0f8475b59f0a8a .av-special-heading-tag .heading-char{ font-size:25px; } .av-special-heading.av-l30ugp1x-c6
Read more
Report
Jaguar Gene Therapy Presents Preclinical Data of JAG101 in Type 1 Galactosemia at American Society of Gene and Cell Therapy 25th Annual Meeting
#top .av-special-heading.av-l30ugp1x-43321fbe2717b9b43ac4df1c9fa3efe6{ padding-bottom:10px; } body .av-special-heading.av-l30ugp1x-43321fbe2717b9b43ac4df1c9fa3efe6 .av-special-heading-tag .heading-char{ font-size:25px; } .av-special-heading.av-l30ugp1x-43
Read more
Report
Show more news